{"id":"bms-986393","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Immune effector cell-associated neurotoxicity syndrome (ICANS)"},{"rate":null,"effect":"Cytopenias"},{"rate":null,"effect":"Infections"}]},"_chembl":{"chemblId":"CHEMBL4303322","moleculeType":"Small molecule","molecularWeight":"518.51"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BMS-986393 involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) that targets CD19, a surface protein commonly found on B-cell malignancies. Once infused back into the patient, these CAR-T cells proliferate and attack CD19-positive cancer cells. This approach leverages the patient's immune system for durable anti-tumor activity.","oneSentence":"BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:43:28.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"},{"name":"Relapsed or refractory chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT06615479","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-03-12","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":440},{"nctId":"NCT06121843","phase":"PHASE1","title":"A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-02-22","conditions":"Multiple Myeloma","enrollment":147},{"nctId":"NCT06297226","phase":"PHASE2","title":"Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-21","conditions":"Multiple Myeloma","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CC-95266","Arlocabtagene autoleucel","arlo-cel","Arlo-cel"],"phase":"phase_3","status":"active","brandName":"BMS-986393","genericName":"BMS-986393","companyName":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","companyId":"juno-therapeutics-inc-a-bristol-myers-squibb-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMS-986393 is a CAR-T cell therapy that redirects patient T cells to recognize and kill cancer cells expressing the CD19 antigen. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Relapsed or refractory chronic lymphocytic leukemia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}